AEM.T 38.05 (+1.44 | +3.93%) AEM 37.38 (+1.51 | +4.21%) SLW.T 25.76 (+0.73 | +2.92%) SLW 25.39 (+0.95 | +3.89%) YRI.T 14.12 (+0.33 | +2.39%) AUY 13.86 (+0.36 | +2.67%) FM.T 17.83 (+0.60 | +3.48%) HBM.T 8.50 (+0.28 | +3.41%) HBM 8.34 (+0.29 | +3.60%) MDI.T 11.50 (+0.32 | +2.86%) TCM.T 3.64 (-0.02 | -0.55%) TC 3.56 (-0.01 | -0.28%) CDM.T 17.13 (-0.01 | -0.06%) CDE 16.80 (0.00 | 0.00%) CSI.T 3.80 (+0.27 | +7.65%) COLUF.O 3.72 (+0.21 | +6.07%) OSK.T 7.31 (+0.29 | +4.13%) PAR.UN.T 7.70 (+0.08 | +1.05%) MT.T (-11.46 | -100.00%) TH.T 1.78 (-0.03 | -1.66%) THER 1.75 (0.00 | 0.00%) ST.T 0.43 (-0.02 | -3.41%) CG.T 9.49 (+0.01 | +0.11%) EDV.T 2.11 (+0.07 | +3.43%) EDVMF.O 2.08 (+0.11 | +5.79%) AHF.T 1.34 (0.00 | 0.00%) MGT.T 1.49 (+0.33 | +28.45%) MGN 1.46 (+0.07 | +5.04%) SSP.V 0.66 (+0.03 | +4.76%) MDG.T 0.43 (+0.01 | +1.18%) AEI.T 0.53 (-0.01 | -1.85%) BCM.V 2.74 (+0.05 | +1.86%) RVM.T 3.55 (+0.05 | +1.43%) RVM 3.49 (+0.15 | +4.49%) MMS.T 0.60 (0.00 | 0.00%) MMSDF.O 0.56 (0.00 | 0.00%) PSD.T 2.20 (0.00 | 0.00%) ATM.V 3.25 (0.00 | 0.00%) PML.V 0.60 (0.00 | 0.00%) DHX.T 0.92 (0.00 | 0.00%) LOR.T 0.35 (-0.05 | -12.50%) R.T 0.79 (+0.02 | +2.60%) CLQ.T 0.40 (-0.01 | -2.47%) CLQMF.O 0.40 (-0.01 | -2.44%) RNX.T 0.43 (-0.01 | -1.16%) FPX.V 0.60 (+0.01 | +1.69%) GTP.V 0.45 (-0.02 | -4.26%) COLTF.O 0.43 (0.00 | 0.00%) NIF.UN.T 5.73 (-0.06 | -1.04%) WOF.V 0.23 (-0.01 | -4.17%) WFEMF.O 0.24 (0.00 | 0.00%) BOZ.V 0.67 (0.00 | 0.00%) SBL.V 0.19 (+0.02 | +8.57%) LAC.T 0.95 (+0.01 | +1.06%) LHMAF.O 1.00 (0.00 | 0.00%) SI.V 0.20 (0.00 | 0.00%) CSQ.V 0.09 (0.00 | 0.00%) CNMXF.O 0.08 (0.00 | 0.00%) NFR.V 0.13 (-0.02 | -10.71%) NFRGF.O 0.13 (-0.00 | -0.76%) EMD.T 0.15 (0.00 | 0.00%) EUU.V 0.18 (0.00 | 0.00%) CEG.T 0.35 (0.00 | 0.00%) CEGMF.O 0.18 (0.00 | 0.00%) FT.T 0.69 (+0.01 | +1.47%) FTMDF.O 0.67 (0.00 | 0.00%) AVR.T 0.53 (-0.02 | -3.64%) AVGCF.O 0.55 (+0.03 | +5.19%) SGD.V 0.07 (0.00 | 0.00%) AAB.T 0.44 (+0.04 | +8.64%) MAD.V 0.31 (+0.01 | +1.67%) MRDDF.O 0.30 (+0.01 | +4.19%) EE.T 1.00 (-0.04 | -3.85%) CRK.T 0.42 (+0.01 | +1.22%) CROCF.O 0.42 (-0.02 | -3.46%) BGC.V 0.27 (0.00 | 0.00%) HRT.T 0.24 (+0.01 | +4.35%) LMA.T 2.44 (-0.01 | -0.41%) LDI.V 0.09 (-0.00 | -5.56%) CT.V 0.04 (0.00 | 0.00%) CTIIF.O 0.04 (0.00 | 0.00%) AMC.T 0.04 (0.00 | 0.00%) AXSMF.O 0.04 (-0.00 | -2.33%) SDI.T 0.20 (0.00 | 0.00%) DIAGF.O 0.19 (0.00 | 0.00%) GMX.T 1.11 (0.00 | 0.00%) GLBXF.O 1.14 (0.00 | 0.00%) MWC.V 0.06 (0.00 | 0.00%) CZO.V 0.13 (+0.01 | +4.17%) MON.V 0.13 (0.00 | 0.00%) SUE.T 0.92 (-0.02 | -2.13%) SDDDF.O 0.89 (0.00 | 0.00%) APE.V 0.08 (-0.01 | -5.88%) BNC.T 0.40 (+0.02 | +5.26%)

Theratechnologies Inc.

TH.T (TSX)
$1.78aaa
Change -0.03 -1.66%
Volume 8,250
52 week Low Hi
  $1.65 $5.15
THER (NASDAQ)
$1.75aaa
Change 0.00 0.00%
Volume 8,882
52 week Low Hi
  $1.68 $5.00
Financial Information
Shares Outstanding: 60,969,769
(As per the latest financial statements)
Fully Diluted Shares: 63,057,898
(As per the latest financial statements)
Est. Market Float: -
Market Cap.: $108,526,189
Last Declared Dividend: -
EPS last 3 months : $(0.12)
EPS Trailing 12 months: $(0.32)
Long-Term Debt: $0
Financial Year-End: Nov 30
Updated: 2012-05-18 11:40
15-20 minutes delay

Renmark Financial Disclaimer

The information contained above was approved by the company presented and is reproduced with its authorization. The accuracy and completeness of that information are the sole responsibility of the said company.

This document is published for general information only and it should not be interpreted as an investment recommendation nor an offer or a solicitation to buy or sell securities issued by the said company. Renmark does not and will not accept any responsibility or liability for investment decisions made on the basis of the information herein contained.

Theratechnologies (TSX:TH)(NASDAQ:THER) is a specialty pharmaceutical company that discovers and develops innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Its first product, EGRIFTA® (tesamorelin for injection), was approved by the United States Food and Drug Administration in November 2010. To date, EGRIFTA® is the only approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.

John-Michel T. Huss, MBA - President and Chief Executive Officer

Luc Tanguay, M.Sc., CFA - Senior Executive Vice President and Chief Financial Officer

Marie-Noël Colussi, CA - Vice President, Finance

Chantal Desrochers, B. Ph., MBA - Vice President, Business Development and Commercialization

Jocelyn Lafond, LL.B., LL.M. - Vice President, Legal Affairs, and Corporate Secretary

Julie Mac Allister, MBA - Vice President, Human Resources

Christian Marsolais, Ph. D. - Vice President, Clinical Research and Medical Affairs

Martine Ortega, Pharm. D. - Vice President, Compliance and Regulatory Affairs

Pierre Perazzelli, B.Sc. - Vice President, Pharmaceutical Development

Krishna Peri, Ph.D. - Vice President, Research

Paul Pommier, MBA - Chairman of the Board

John-Michel T. Huss, MBA - Director

Luc Tanguay, M.Sc., CFA - Director

Gilles Cloutier, Ph.D. - Corporate Director

Robert G. Goyer, Ph.D. - Emeritus Professor, Faculty of Pharmacy of Université de Montréal

Gérald A. Lacoste, Q.C. - Corporate Director

Bernard Reculeau - Corporate Director

Jean-Denis Talon - Chairman, Axa Canada

Headquarters:

2310 Alfred-Nobel Blvd.
Montréal, Québec
H4S 2B4 Canada

Telephone: (514) 336-7800
Fax: (514) 336-7242

For additional info., contact
Barry Mire
Bettina Filippone

Montréal

Telephone: (514) 939-3989
Fax: (514) 939-3717

Toronto

Telephone: (416) 644-2020
Fax: (416) 644-2021
Home Theratechnologies Inc.